23 Feb MEDIPOST
Antonio Lee, Ph.D., CEO
Oct. 6 | 3:15pm | FLW Ballroom F
Cambridge, MA
(Private)
MEDIPOST (KOSDAQ 078160) is headquartered in South Korea, with its wholly-owned subsidiaries in the U.S. (MEDIPOST Inc.) and Japan (MEDIPOST K.K.), as well as a CGT CDMO (OmniaBio Inc.) joint-venture subsidiary based in Ontario, Canada. CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs with hyaluronic acid composite administered surgically) received BLA approval in 2012 in Korea, for the treatment of knee articular cartilage defects (ICRS grade IV) in patients with osteoarthritis (K&L grade II or III) without age-limit. Over 33,500+ patients have been treated with CARTISTEM® in Korea with an excellent long-term safety and efficacy profile. Currently, on-market Korean RWE study is underway for the demonstration of long-term health-economic benefit. In Japan, CARTISTEM® Phase III pivotal trial will be completed in 2025, while the Phase III pivotal trial in the U.S. will begin in 2026.
MEDIPOST’s other clinical-stage MSC pipelines focus on early-stage osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD).
